Primary hyperparathyroidism in pregnancy after in vitro fertilization

Primary hyperparathyroidism (PHPT) in pregnant women is a rare condition, often remaining undiagnosed due to non-specific clinical symptoms. However, it can lead to life-threatening complications for both the mother and fetus. In vitro fertilization (IVF) is also associated with an increased probability of adverse outcomes compared to the general population. Timely diagnostics and personalized treatment, taking into account the extremely high risk of complications if PHPT and pregnancy result from IVF, require attention of healthcare professionals and formation of a multidisciplinary team.

1. Minisola S., Arnold A., Belaya Z. et al. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J Bone Miner Res. 2022;37(11):2315–29. https://doi.org/10.1002/jbmr.4665.

2. Ali D.S., Dandurand K., Khan A.A. Primary hyperparathyroidism in pregnancy: literature review of the diagnosis and management. J Clin Med. 2021;10(13):2956. https://doi.org/10.3390/jcm10132956.

3. Mokrysheva N.G., Lipatenkova A.K., Taller N.A. Primary hyperparathyroidism and pregnancy [Pervichnyj giperparatireoz i beremennost']. Akusherstvo i ginekologiya. 2016;(10):18–25. (In Russ.). https://doi.org/10.18565/aig.2016.10.18-25.

4. Schnatz P.F., Curry S.L. Primary hyperparathyroidism in pregnancy: evidence-based management. Obstet Gynecol Surv. 2002;57(6):365–76. https://doi.org/10.1097/00006254-200206000-00022.

5. Order of the Ministry of Health of Russia dated of October 20, 2020 No. 1130n "On approval of the Procedure for providing medical care in the field of obstetrics and gynecology". [Prikaz Minzdrava Rossii ot 20.10.2020 № 1130n «Ob utverzhdenii Poryadka okazaniya medicinskoj pomoshchi po profilyu "akusherstvo i ginekologiya"»]. Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2020. 688 p. (In Russ.). Available at: https://base.garant.ru/74840123/. [Accessed: 15.10.2023].

6. Hacker A.N., Fung E.B., King J.C. Role of calcium during pregnancy: maternal and fetal needs. Nutr Rev. 2012;70(7):397–409. https://doi.org/10.1111/j.1753-4887.2012.00491.x.

7. McCarthy A., Howarth S, Khoo S. et al. Management of primary hyperparathyroidism in pregnancy: a case series. Endocrinol Diabetes Metab Case Rep. 2019;2019:19-0039. https://doi.org/10.1530/EDM-19-0039. Online ahead of print.

8. Nastos C., Paspala AS., Mavroeidi I. et al. Surgical management of primary hyperparathyroidism during pregnancy: a systematic review of the literature. Gynecol Endocrinol. 2021;37(12):1086–95. https://doi.org/10.1080/09513590.2021.1932801.

9. Iqbal N., Steinberg H., Aldasouqi S., Edmondson J.W. Nephrolithiasis during pregnancy secondary to primary hyperparathyroidism. Urology. 2001;57(3):554. https://doi.org/10.1016/s0090-4295(00)01061-x.

10. Kovacs C.S. Maternal mineral and bone metabolism during pregnancy, lactation, and post-weaning recovery. Physiol Rev. 2016;96(2):449–547. https://doi.org/10.1152/physrev.00027.2015.

11. Mokrysheva N.G., Krupinova J.A., Voronkova I.A. Parathyroid glands: the normal development, anatomy and histological structure. [Okoloshchitovidnye zhelezy: normal'noe razvitie, anatomicheskoe i gistologicheskoe stroenie]. Endokrinnaya hirurgiya. 2018;12(4):178–87. (In Russ.). https://doi.org/10.14341/serg10039.

12. Hu Y., Cui M., Sun Z. et al. Clinical presentation, management, and outcomes of primary hyperparathyroidism during pregnancy. Int J Endocrinol. 2017;2017:3947423. https://doi.org/10.1155/2017/3947423.

13. Rigg J., Gilbertson E., Barrett H.L. et al. Primary hyperparathyroidism in pregnancy: maternofetal outcomes at a quaternary referral obstetric hospital, 2000 Through 2015. J Clin Endocrinol Metab. 2019;104(3):721– 9. https://doi.org/10.1210/jc.2018-01104.

14. DiMarco A.N., Meeran K., Christakis I. et al. Seventeen cases of primary hyperparathyroidism in pregnancy: a call for management guidelines. J Endocr Soc. 2019;3(5):1009–21. https://doi.org/10.1210/js.2018-00340.

15. Herman T., Csehely S., Orosz M. et al. Impact of endocrine disorders on IVF outcomes: results from a large, single-centre, prospective study. Reprod Sci. 2023;30(6):1878–90. https://doi.org/10.1007/s43032-022-01137-0.

16. Arshad M.F., Arambewela M.H., Bennet W.M. et al. Primary hyperparathyroidism in pregnancy: experience of a tertiary centre. Primary hyperparathyroidism in pregnancy: experience of a tertiary centre. Surg Today. 2023;53(4):470–5. https://doi.org/10.1007/s00595-022-02583-8.

17. Strebeck R.J., Schneider A.M., Whitcombe D.D. et al. Hyperparathyroidism in pregnancy: a review of the literature. Obstet Gynecol Surv. 2022;77(1):35–44. https://doi.org/10.1097/OGX.0000000000000977.

18. Sabban H., Zakhari A., Patenaude V. et al. Obstetrical and perinatal morbidity and mortality among in-vitro fertilization pregnancies: a population-based study. Arch Gynecol Obstet. 2017;296(1):107–13. https://doi.org/10.1007/s00404-017-4379-8.

19. Cong X., Shen L., Gu X. Current opinions on nephrolithiasis associated with primary hyperparathyroidism. Urolithiasis. 2018;46(5):453–7. https://doi.org/10.1007/s00240-018-1038-x.

20. Behrens M., Boyle S., Fingeret A.L. Evaluation for primary hyperparathyroidism in patients who present with nephrolithiasis. J Surg Res. 2021;257:79–84. https://doi.org/10.1016/j.jss.2020.07.049.

21. Chiodini I., Cairoli E., Palmieri S. et al. Non classical complications of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(6):805–20. https://doi.org/10.1016/j.beem.2018.06.006.

22. Tournis S., Makris K., Cavalier E. et al. Cardiovascular risk in patients with primary hyperparathyroidism. Curr Pharm Des. 2020;26(43):5628–36. https://doi.org/10.2174/1381612824999201105165642.

23. Jiao H.N., Sun L.H., Liu Y. et al. Multidisciplinary team efforts to improve the pregnancy outcome of pregnancy complicated with primary hyperparathyroidism: case series from a single hospital. BMC Pregnancy Childbirth. 2021;21(1):576. https://doi.org/10.1186/s12884-021-04042-7.

24. Mokrysheva N.G., Eremkina A.K., Mirnaya S.S. et al. The clinical practice guidelines for primary hyperparathyroidism, short version. [Klinicheskie rekomendacii po pervichnomu giperparatireozu, kratkaya versiya]. Problemy endokrinologii. 2021;67(4):94–124. (In Russ.). https://doi.org/10.14341/probl12801.

25. Bollerslev J., Rejnmark L., Zahn A. et al. European Expert Consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). Eur J Endocrinol. 2022;186(2):R33–R63. https://doi.org/10.1530/EJE-21-1044.

26. Chen Y., Pedersen L.H., ChuW.W., Olsen J. Drug exposure side effects from mining pregnancy data. ACM SIGKDD Explorations Newsletter. 2007;9(1):22–9. https://doi.org/10.1145/1294301.1294308.

27. Krysiak R., Wilk M., Okopien B. Recurrent pancreatitis induced by hyperparathyroidism in pregnancy. Arch Gynecol Obstet. 2011;284(3):531–4. https://doi.org/10.1007/s00404-010-1668-x.

28. Levy S., Fayez I., Taguchi N. et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009;44(3):428–30. https://doi.org/10.1016/j.bone.2008.11.001.

29. Horjus C., Groot I., Telting D. et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. J Pediatr Endocrinol Metab. 2009;22(8):741– 9. https://doi.org/10.1515/jpem.2009.22.8.741.

30. Boyce R.W., Varela A., Chouinard L. et al. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetroticlike skeletal phenotype at birth and in the early postnatal period. Bone. 2014;64:314–25. https://doi.org/10.1016/j.bone.2014.04.002.

31. Okamatsu N., Sakai N., Karakawa A. et al. Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns. Biochem Biophys Res Commun. 2017;491(3):614–21. https://doi.org/10.1016/j.bbrc.2017.07.154.

32. Pothiwala P., Levine S.N. Parathyroid surgery in pregnancy: review of the literature and localization by aspiration for parathyroid hormone levels. J Perinatol. 2009;29(12):779–84. https://doi.org/10.1038/jp.2009.84.

33. Schnatz P.F., Thaxton S. Parathyroidectomy in the third trimester of pregnancy. Obstet Gynecol Surv. 2005;60(10):672–82. https://doi.org/10.1097/01.ogx.0000180889.23678.fb.

34. Brychta I., Mayer A., Gergel M. et al. Primary hyperparathyroidism in pregnancy: a case of successful parathyroidectomy in the third trimester. Neuro Endocrinol Lett. 2021;42(8):517–21.

35. Sharma S.G., Levine S.N., Yatavelli R.K. et al. Parathyroidectomy in first trimester of pregnancy. J Endocr Soc. 2020;4(3):bvaa015. https://doi.org/10.1210/jendso/bvaa015.

36. Vitetta G.M., Neri P., Chiecchio A. et al. Role of ultrasonography in the management of patients with primary hyperparathyroidism: retrospective comparison with technetium-99m sestamibi scintigraphy. J Ultrasound. 2014;17(1):1–12. https://doi.org/10.1007/s40477-014-0067-8.

37. Committee Opinion No. 723: Guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol. 2017;130(4):e210–e216. https://doi.org/10.1097/AOG.0000000000002355.

38. Bunch P.M., Kelly H.R. Preoperative imaging techniques in primary hyperparathyroidism: a review. JAMA Otolaryngol Head Neck Surg. 2018;144(10):929–37. https://doi.org/10.1001/jamaoto.2018.1671.

39. Kuznetsov N.S., Kim I.V., Kuznetsov S.N. Intraoperative parathyroid hormone in strategy of surgical treatment of a primary hyperparathyreosis. [Intraoperacionnoe opredelenie paratgormona v strategii hirurgicheskogo lecheniya pervichnogo giperparatireoza]. Endokrinnaya hirurgiya. 2011;5(2):18–25. (In Russ.). https://doi.org/10.14341/2306-3513-2011-2-18-25.

40. Pavlidis E.T., Pavlidis T.E. Update on the current management of persistent and recurrent primary hyperparathyroidism after parathyroidectomy. World J Clin Cases. 2023;11(10):2213–25. https://doi.org/10.12998/wjcc.v11.i10.2213.

41. He C., Zhang Y., Li L. et al. Risk factor analysis and prediction of severe hypocalcemia after total parathyroidectomy without auto-transplantation in patients with secondary hyperparathyroidism. Int J Endocrinol. 2023;2023:1901697. https://doi.org/10.1155/2023/1901697.

42. Shahriarirad R., Meshkati Y.S.M., Ardekani A. et al. Calcitriol supplementation before parathyroidectomy and calcium level after surgery in parathyroid adenoma patients: a randomized controlled trial. J Endocrinol Invest. 2023;46(5):985–90. https://doi.org/10.1007/s40618-022-01963-8.

43. Rana S., Lemoine E., Granger J.P., Karumanchi S.A. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094–112. https://doi.org/10.1161/CIRCRESAHA.118.313276.

44. Tomimatsu T., Mimura K., Matsuzaki S. et al. Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors. Int J Mol Sci. 2019;20(17):4246. https://doi.org/10.3390/ijms20174246.

45. Gorbacheva A.M., Bibik E.E., Dobreva E.A. et al. Soluble endoglin as a perspective marker of endothelial dysfunction in patients with primary hyperparathyroidism: a pilot study. [Rastvorimyj endoglin – potencial'nyj marker endotelial'noj disfunkcii u pacientov s pervichnym giperparatireozom: pilotnoe issledovanie]. Ozhirenie i metabolizm. 2022;19(4):358–68. (In Russ.). https://doi.org/10.14341/omet12923.

46. Gambardella J., De Rosa M., Sorriento D. et al. Parathyroid hormone causes endothelial dysfunction by inducing mitochondrial ROS and specific oxidative signal transduction modifications. Oxid Med Cell Longev. 2018;2018:9582319. https://doi.org/10.1155/2018/9582319.

47. Colak S., Aydogan B.I., Canpolat A.G. et al. Is primary hyperparathyroidism a cause of endothelial dysfunction? Clin Endocrinol (Oxf). 2017;87(5):459–65. https://doi.org/10.1111/cen.13418.

48. Vadana M., Cecoltan S., Ciortan L. et al. Parathyroid hormone induces human valvular endothelial cells dysfunction that impacts the osteogenic phenotype of valvular interstitial cells. Int J Mol Sci. 2022;23(7):3776. https://doi.org/10.3390/ijms23073776.

49. Hultin H., Hellman P., Lundgren E. et al. Association of parathyroid adenoma and pregnancy with preeclampsia. J Clin Endocrinol Metab. 2009;94(9):3394–9. https://doi.org/10.1210/jc.2009-0012.